Bio-Techne Corporation (TECH) AI Stock Analysis

Bio-Techne Corporation specializes in the development, manufacturing, and global distribution of life science reagents, instruments, and services for research and clinical diagnostic markets. Operating through Protein Sciences and Diagnostics and Genomics, the company supplies critical inputs for scientific discoveries and medical diagnostics. Protein Sciences provides biological reagents such as cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, as well as proteomic analytical tools for automated western blot and multiplexed ELISA workflows. Diagnostics and Genomics develops diagnostic controls, calibrators, exosome-based assays, spatial genomic tissue-based assays, and genetic and oncology kits.

Bio-Techne grew revenue at a 5-year CAGR of 5.5% from FY2021 to FY2026, expanding from $1.11B in FY2022 to $1.22B in FY2026. Annual revenue growth was 18.7% in FY2022, 2.8% in FY2023, 2.0% in FY2024, and 5.2% in FY2025, before contracting 0.4% in FY2026. Operating margin was 20.7% in FY2026, up from 8.4% in FY2025, while gross margin stood at 65.8%. Net income recovered to $181.9M in FY2026 from $73.4M in FY2025, resulting in diluted EPS of $1.84 compared to $1.98 in FY2022. In the latest quarter ended June 30, 2026, quarterly revenue grew 1.3% year-over-year and quarterly earnings grew 128.6%.

As of June 30, 2026, Bio-Techne held $264.7M in cash and short-term investments against total debt of $289.1M, resulting in net debt of $24.4M. Its current ratio was 4.55 and debt-to-equity was 0.14 against $2.11B in shareholders' equity. For FY2026, operating cash flow reached $292.1M and capital expenditures were $28.9M, producing free cash flow of $263.2M. Capital deployment during the year included $41.7M in share buybacks and $49.9M in dividends paid, contributing to a 5-year share count reduction of 4.7%.

At a last close of $72.57, Bio-Techne carries a market capitalization of $11.38B. The stock trades at a trailing P/E of 62.6x and a forward P/E of 34.6x, compared to the median of its S&P 500 Healthcare peers at 27.2x and 16.5x, respectively. Its EV/EBITDA of 32.8x is also higher than the peer median of 15.0x. Over the past year, TECH delivered a return of 18.6%, outperforming the S&P 500 (SPY) return of 16.8%. However, its 5-year return of -40.1% lagged the S&P 500 return of 83.0%.

Bio-Techne pays a forward annual dividend of $0.32 per share, representing a dividend yield of 0.44% and a payout ratio of 17.4%. The dividend is distributed quarterly and has been paid for 19 consecutive years, with a 5-year annualized dividend growth rate of 0.0%. The company's last ex-dividend date was August 24, 2026.

Wall Street analyst ratings comprise 1 Strong Buy and 12 Hold recommendations, with zero Buy, Sell, or Strong Sell ratings. The mean price target is $70.50, which sits 2.9% below the last close of $72.57. For the fiscal year ending June 30, 2027, consensus estimates project revenue of $1.27B and EPS of $2.04. Over the last four quarters, Bio-Techne delivered 2 EPS beats. The company is scheduled to report its next earnings on November 4, 2026.

This page is an AI-written research summary of Bio-Techne Corporation (TECH). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: TECH income statement, TECH balance sheet, TECH key metrics, TECH analyst forecast, TECH chart. See the TECH stock overview for the latest quote and news.